Shuttle Pharmaceuticals (NASDAQ:SHPH) Announces Quarterly Earnings Results

by · The Cerbat Gem

Shuttle Pharmaceuticals (NASDAQ:SHPH – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.43) earnings per share for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Stock Up 4.0%

Shares of NASDAQ SHPH traded up $0.03 during midday trading on Friday, reaching $0.67. 454,298 shares of the stock were exchanged, compared to its average volume of 2,360,916. The firm has a 50-day simple moving average of $0.85 and a two-hundred day simple moving average of $1.47. Shuttle Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $6.19. The firm has a market cap of $3.72 million, a price-to-earnings ratio of -0.06 and a beta of 0.38.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

View Our Latest Research Report on SHPH

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $124,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. Finally, Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .

See Also